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Abstract 
Background 
Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular disease 
and mortality throughout all stages of chronic kidney disease (CKD), independent from 
established risk factors and markers of mineral homeostasis. The relation of FGF23 with 
other renal and non-renal cardiovascular risk factors is not well established. 
Methods 
Using stored samples, plasma FGF23 was determined in 604 patients with moderate to severe 
kidney disease that participated in the MASTERPLAN study (ISRCTN73187232). The 
association of FGF23 with demographic and clinical parameters was evaluated using 
multivariable regression models. 
Results 
Mean age in the study population was 60 years and eGFR was 37 (±14) ml/min/1.73 m2. 
Median proteinuria was 0.3 g/24 hours [IQR 0.1-0.9]. FGF23 level was 116 RU/ml [67–203] 
median and IQR. Using multivariable analysis the natural logarithm of FGF23 was positively 
associated with history of cardiovascular disease (B = 0.224 RU/ml; p = 0.002), presence of 
diabetes (B = 0.159 RU/ml; p = 0.035), smoking (B = 0.313 RU/ml; p < 0.001), phosphate 
level (B = 0.297 per mmol/l; p = 0.0024), lnPTH (B = 0.244 per pmol/l; p < 0.001) and 
proteinuria (B = 0.064 per gram/24 hrs; p = 0.002) and negatively associated with eGFR 
(B = −0.022 per ml/min/1.73 m2; p < 0.001). 
Conclusions 
Our study demonstrates that in patients with CKD, FGF23 is related to proteinuria and 
smoking. We confirm the relation between FGF23 and other cardiovascular risk factors. 
Keywords 
Cardiovascular disease, CKD, FGF23, Phosphate, Proteinuria, Smoking 
Background 
Chronic kidney disease (CKD) is a well-established risk factor for cardiovascular disease and 
mortality [1]. The added risk of CKD is both graded, depending on stage of disease, as well 
as independent from traditional cardiovascular risk factors. Many studies, both experimental 
and epidemiological, have tried to define the components typical for CKD that carry this 
added risk. Proteinuria[2], malnutrition, deranged homeostasis of calcium and phosphate, 
vitamin D deficiency, anemia, and hyperparathyroidism have all been implicated to be 
involved. Recently, fibroblast growth factor 23 (FGF23) was identified as a novel risk factor 
not only in patients with end stage kidney disease[3] and advanced stages of CKD[4,5], but 
also in patients in the early stages of CKD and in the general population[6]. Since FGF23 has 
an important role in the regulation of mineral balance and vitamin D metabolism, it is 
intriguing that its contribution to the increased risk was independent from calcium, phosphate 
and vitamin D. These observations supported the hypothesis that FGF23 may exert biological 
and possibly pathological effects that are not mediated through calcium, phosphate or vitamin 
D. Theoretically FGF23 could have direct toxic effects or influence non-mineral 
cardiovascular risk factors. Indeed it was suggested that FGF23 influenced vascular function 
in humans [7] and was associated with heart function and atherosclerosis [8]. Most recently, 
strong evidence suggested a direct role for FGF23 as an inducer of left ventricular 
hypertrophy in a mouse model [9]. 
In the current study we investigated the association of FGF23 with established cardiovascular 
risk factors, and with additional specific renal risk factors for cardiovascular disease in a 
large well-described cohort of patients with moderate to severe CKD. The mutual 
relationship between FGF23 and these established risk factors could provide important clues 
for future therapy, aiming at reducing cardiovascular risk. 
Methods 
Patients 
For the current study patients from the MASTERPLAN study were used [10]. The 
MASTERPLAN study was centrally approved by the medical ethical committee of UMCU 
(METC, University medical center Utrecht), and locally by all participating centers. Criteria 
for patient eligibility and methods of data collection of MASTERPLAN have been described 
previously. In short, MASTERPLAN is a randomized controlled clinical trial 
(ISRCTN73187232), performed in nine Dutch hospitals. 788 patients with CKD (eGFR 20–
70 ml/min/1.73 m2) were randomized to either receive usual care by the nephrologist or 
intensified treatment with added nurse practitioner support. All participants gave written 
informed consent. The primary end point is a composite of fatal and nonfatal myocardial 
infarction, stroke and cardiovascular mortality. Inclusion started in 2004 and ended in 
December 2005. 
For the current analysis we retrieved blood samples collected at baseline by the patients that 
participated in the MASTERPLAN study. We excluded patients who had received a kidney 
transplant (n = 184). 
Data collection 
Baseline measurements included a questionnaire recording smoking behavior, physical 
activity and medication use. Physical examination consisted of measurement of height, 
weight and blood pressure. Blood was drawn and a 24-hour urine sample was collected. 
Blood and urine samples were analyzed by the laboratory of the local center. Medical history 
was obtained from the medical records. History of CV disease was defined as a history of 
myocardial infarction, ischemic stroke or vascular intervention. Diabetes mellitus was 
defined as the use of glucose lowering drugs or a fasting glucose >126 mg/dl (7.0 mmol/l). 
FGF23 and vitamin D measurements 
EDTA-plasma has been stored at −80˚ C until use. In these samples c-terminal FGF23 was 
determined in duplicate using a sandwich ELISA (Immutopics, San Clemente CA) with an 
intra-assay and interassay coefficient of variation of <5% and <16% respectively [11]. 
Glomerular filtration rate was estimated (eGFR) with the four-point MDRD formula [12]. 
Proteinuria was determined in 24-hour urine collections. 
In selected samples that were used for the FGF23 assay, both 25vitD and 1,25vitD were 
determined using a RIA (Diasorin, Stillwater, MN and IDS, Tyne and Wear, United 
Kingdom, respectively). Intra-assay and interassay coefficient of variation were <7% and 
<10% for D25 and <9% and <11% for 1,25D respectively. 
Statistical analysis 
Using multivariable analysis the relation of FGF23 with classical risk factors for 
cardiovascular disease was studied (model 1, sex, age, blood pressure, presence of diabetes, 
prior cardiovascular disease, baseline body mass index (BMI) and total cholesterol levels). 
Next, in the fully adjusted model, the so-called “renal risk factors” were added to the model, 
and the use of active vitamin D (model 2: model 1 plus calcium, phosphate, PTH, eGFR, 
proteinuria, and use of active vitamin D). To study a possible graded relation between 
proteinuria and FGF23, all patients were divided, according to the degree of proteinuria: 1) 
no proteinuria; 2) proteinuria < 0.5 gram/24 hours; 3) proteinuria between 0.5 and 2.0 
gram/24 hours and 4) proteinuria > 2 gram/24 hours. For skewed data (like FGF23) log-
transformation was performed. As we found during analysis an association between 
proteinuria and FGF23, we subsequently determined serum level of 25vitD and 1,25vitD in 
all patients with proteinuria >2 gram/24 hours (n = 63) and in a random sample of equal size 
of patients with proteinuria <2 gram/24 hours, to study the possible confounding effects of 
vitamin D levels on this relation. The threshold of 2 gram/24 hours was arbitrarily chosen to 
have a sufficient number of patients above this level. In this subgroup multivariable analysis 
was performed with FGF23 as dependent variable, and levels of vitamin D were added to the 
fully adjusted model 2. A dichotomous variable was subsequently used (presence or absence 
of proteinuria above 2 grams/24 hours) to account for the categorical effect of high-
proteinuria on FGF23 levels. 
Results 
Patients 
For 604 patients at baseline a plasma sample was available for determination of FGF23, and 
all these patients were included. Mean age was 60.2 (sd 12.5) years, 69% was male and mean 
eGFR was 37 (sd 14) ml/min/1.73 m2. All other baseline characteristics are shown in Table 1. 
Table 1 Baseline characteristics 
Variable N(%) = 604(100%) 
Gender (male) 417(69%) 
Age (yrs) 60.2(± 12.5) 
BMI (kg/m2) 26.5(24.3-29.4) 
Race (Caucasian) 560(92.7) 
Cause of CKD  
Diabetic nephropathy 65(10.8%) 
Renovascular 188(31.1%) 
Glomerular disease 109(18%) 
Interstitial disease 57(9.4%) 
Congenital (incl PKD) 62(10.3%) 
Unknown 123(20.4%) 
History of CVD 178(29.5%) 
Diabetes Mellitus 144(23.8%) 
Hypertension 433(71.7%) 
Smoking 145(24%) 
Systolic BP (mmHg) 136(±21) 
Diastolic BP (mmHg) 78(±11) 
Creatinine (µmol/l) 184(±71) 
eGFR (MDRD, ml/min/1.73 m2) 36.8(±13.9) 
Total cholesterol (mmol/l) 4.8(±1.0) 
Proteinuria (g/24 hours) 0.3(0.1-0.9) 
Phosphate (mmol/l) 1.12(±0.26) 
Calcium (mmol/l) 2.38(±0.14) 
PTH (pmol/l) 8.3(5.6-14.4) 
cFGF23 (RU/ml) 116(67–203) 
Medication  
Active vitamin D (any) 135(22.4) 
Phosphate binders (any) 56(9.3) 
Values are given as N (%), mean and standard deviations (±SD) for normally distributed data 
and medians and interquartile ranges (25%-75%) for skewed data. 
CKD: chronic kidney disease; PKD: polycystic kidney disease; CVD: cardiovascular disease; 
BP: blood pressure; eGFR: estimated glomerular filtration rate; MDRD: four-point MDRD 
formula. 
Fibroblast growth factor 23 and classical cardiovascular risk factors (model 1) 
In multivariable regression analysis (Table 2), combining established cardiovascular risk 
factors, BMI (β = 0.105; p = 0.011), history of cardiovascular disease (β = 0.1; p = 0.018) and 
smoking (β = 0.136; p = 0.001) were positively associated with FGF23, while male sex was 
inversely associated with FGF23 (β = 0.89; p = 0.032). The relationship between smoking and 
FGF23 is shown in Figure 1. 
Table 2 Model 1: FGF23 and traditional cardiovascular risk factors 
Variable B Standard error Beta p-value 
Male −0.174 −0.081 −0.89 0.032 
Age (year) −0.003 −0.003 −0.041 0.354 
Systolic blood pressure (mmHg) 0.002 0.002 0.043 0.308 
Smoking 0.288 0.086 0.136 0.001 
BMI 0.021 0.008 0.105 0.011 
Diabetes Mellitus 0.154 0.089 0.073 0.084 
Total cholesterol (mmol/l) 0.003 0.037 0.004 0.930 
History CVD 0.198 0.084 0.100 0.018 
Model 1: Relation of lnFGF23 with Framingham risk factors for cardiovascular disease after 
multivariable analysis. B reflects change in lnFGF23 per unit of the respective variable. For 
dichotomous variables (sex, smoking, diabetes, and history of CVD) B reflects lnFGF23 
change in the presence of the depicted variable. Beta is the standardized B to compare 
influence on lnFGF23 between variables. BMI: Body mass index; CVD: cardiovascular 
disease 
Figure 1 Relation of smoking with FGF23. FGF23 was log transformed and adjusted for 
eGFR, phosphate, natural logarithm of PTH, calcium, history of cardiovascular disease and 
history of diabetes mellitus. The error bars represent the standard error of the mean. 
Fibroblast growth factor 23 in the fully adjusted model (model 2) 
In this fully adjusted model, history of cardiovascular disease (β = 0.113; p = 0.002), presence 
of diabetes (β = 0.075; p = 0.035), smoking (β = 0.148; p < 0.001), phosphate level (β = 0.082; 
p = 0.024), PTH (β = 0.196; p < 0.001) and proteinuria (β = 0.113; p = 0.002) were positively 
associated with FGF23, while eGFR had an inverse association with FGF23 (β = −0.34; 
p < 0.001). After categorizing the level of proteinuria, a graded relationship between amount 
of proteinuria and adjusted level of FGF23 was revealed (Figure 2). All other factors had no 
significant association with FGF23 (Table 3). 
Figure 2 Relation between proteinuria and FGF23. FGF23 was log transformed and 
adjusted for eGFR, phosphate, natural logarithm of PTH, calcium, smoking, history of 
cardiovascular disease and history of diabetes mellitus. Categories of albuminuria: 1) no 
proteinuria; 2) proteinuria < 0.5 gram/24 hours; 3) proteinuria between 0.5 and 2.0 gram/24 
hours and 4) proteinuria > 2 gram/24 hours. The error bars represent the standard error of the 
mean. 
Table 3 Model 2. Relation of lnFGF23 in the full adjusted model with cardiovascular 
and renal risk factors 
Variable B Standard error Beta p-value 
eGFR (MDRD, ml/min/1.73 m2) −0.022 0.003 −034 <0.001 
Phosphate (mmol/l) 0.297 0.131 0.082 0.024 
lnPTH (pmol/l) 0.244 0.047 0.196 <0.001 
Calcium (mmol/l) 0.393 0.220 0.062 0.075 
Proteinuria (gram/24 hours) 0.064 0.021 0.113 0.002 
Male −0.094 0.071 −0.048 0.183 
Smoking 0.313 0.073 0.148 <0.001 
BMI 0.003 0.007 0.017 0.638 
Diabetes Mellitus 0.159 0.075 0.075 0.035 
History CVD 0.224 0.071 0.113 0.002 
Age (year) 0.001 0.003 0.006 0.868 
Systolic blood pressure (mmHg) −0.001 0.002 −0.02 0.586 
Total cholesterol (mmol/l) 0.006 0.031 0.007 0.848 
Active vitamin D use 0.096 0.079 0.044 0.223 
Model 2: multivariable analyses of relation of lnFGF23 with Framingham risk factors (model 
1) and renal risk factors. B reflects change in lnFGF23 per unit change in the variable. For 
dichotomous variables (sex, smoking, diabetes, and history of CVD) B reflects lnFGF23 
change in the presence of the depicted variable. Beta is the standardized B to compare 
influence on lnFGF23 between variables. 
eGFR: estimated glomerular filtration rate; MDRD: four-point MDRD-formula; BMI: Body 
mass index; CVD: cardiovascular disease 
Role of vitamin D status on the relationship between proteinuria and 
fibroblast growth factor 23 
Since the relation between proteinuria, FGF23 and eGFR may be modulated by vitamin D 
status, levels of both 25vitD and 1,25vitD were determined in patients with proteinuria > 2 
gr/24 hours (n = 63) and a random sample of equal size of those with proteinuria < 2 gr/24 
hours. Levels of 25vitD were 51 (± 23) and 67 (± 24) nmol/l (non-significant) and levels of 
1,25vitD were 44 (± 26) and 53 (± 25) pmol/l (p = 0.05) in patients with proteinuria >2 gr/24 
hours and patients with proteinuria <2 gr/24 hours respectively. Details of these individuals 
are shown in Table 4. 
Table 4 Baseline characteristics of subgroups with and without proteinuria >2 gram/24 
hours 
Variable Prot < 2 g/24 hrs Prot > 2 g/24 hrs p-value 
N 63 63  
eGFR (ml/min/1.73 m2) 36.5 (±14.1) 29.0(±12.0) 0.002 
Phosphate (mmol/l) 1.09(±0.20) 1.19(±0.24) 0.01 
Proteinuria (g/24 hrs) 0.28[0.09-0.80] 3.30[2.60-5.50] <0.001* 
PTH (pmol/l) 8(5–12) 11(7–20) 0.002 
cFGF23 (RU/ml) 106[65–186] 172[100–242] 0.002 
25OD-D3 (nmol/l) 67(±25) 51(±24) 0.001 
1,25(OH)2−D3 (pmol/l) 53(±25) 44(±26) 0.05 
Active vitamin D use (%) 21 37 0.05 
Values are given as means (±SD) or medians [IQR]. 
*Per definition 
In this subpopulation, levels of either 25D or 1,25D had no relation with FGF23 levels (p-
values were 0.71 and 0.64 respectively). Phosphate level and smoking were positively 
associated, and eGFR negatively associated with FGF23 in this sub analysis. The magnitudes 
of the associations in this substudy were similar as in the entire cohort. In addition, the use of 
active vitamin D, as was assessed in the full data set and shown in Table 3, had no significant 
association with the level of FGF23. 
Discussion 
Our study demonstrates that in patients with CKD FGF23 is significantly associated with 
smoking and proteinuria (Figures 1 & 2). This association was strong and persisted after 
correcting for other well known cardiovascular and renal risk factors. In the fully adjusted 
model (Table 3) both smoking and proteinuria had a relatively high impact on FGF23 levels 
that was exceeded by eGFR and PTH only. Our data confirm the established relationship 
between FGF23 on the one hand and phosphate level, eGFR and PTH on the other [13]. This 
relationship possibly has a biological basis as FGF23 is physiologically regulated by 
phosphate levels [14], phosphate loading [15] and PTH [16]. 
Our observation of the association between smoking and FGF23 is novel. Possible 
explanations for this association are an influence of smoking on FGF23 production, an 
influence of smoking on FGF23 sensitivity or mere confounding by other factors that directly 
influence FGF23 levels. Smoking may increase FGF23 levels by affecting the metabolism of 
bone, the primary source of FGF23. Indeed, several studies have observed an association of 
smoking with osteoporosis [17,18]. However, there are no experimental data to support the 
assumption that smoking increases FGF23 production. Furthermore, if smoking directly 
increases FGF23 levels, we would have expected lower phosphate levels in smokers, which 
were not observed. Therefore, we consider it more likely that smoking reduces FGF23 
sensitivity, thus necessitating an increased production to maintain phosphate excretion. The 
FGF23 receptor consists of heterodimerized FGFR1 and klotho, and is primarily located in 
the parathyroid and distal tubular cells in the kidney [19]. The expression of klotho is 
downregulated by oxidative stress [20], leading to dismantling of a functional FGF23-
receptor. For this reason it is possible that smoking, via increased oxidant stress, decreases 
the number of functional FGF23 receptors in the kidney [21]. We cannot exclude the 
possibility that the association between FGF23 and smoking resulted from confounding by 
factors such as other life style differences between smokers and non-smokers. In contrast to 
others [22] we did not find a relation between body mass index and FGF23, in the full-
adjusted model. The population studied by Marsell however was older, had better estimated 
GFR, and lower levels of FGF23. The putative relative contribution of BMI on FGF23 levels 
in the MASTERPLAN cohort may be overwhelmed by other factors, shown in Table 3. The 
relation we found between smoking and levels of FGF23 is in line with a recent study that 
addressed the predictive value of FGF23 on death and progression to end stage kidney 
disease [23]. In that study, the proportion of smokers increased in the higher quartiles of 
FGF23, however, the quantitative effect of smoking on FGF23 was not assessed. Correcting 
for several factors including smoking did not mitigate the strength of the association between 
FGF23 and the risk of death. However this does not imply that smoking cannot increase 
levels of FGF23. In another recent study in the general population, the percentage smokers 
did not differ between tertiles according to levels of FGF23 [24]. Whether higher FGF23 
levels exist within individual tertiles among smokers, as compared with non-smokers, was 
not assessed. 
The second major finding in our study is the graded relationship of FGF23 with proteinuria 
(Figure 2). This association can be explained in several ways. First it is possible that FGF23 
has a direct effect on the glomerular filtration barrier, possibly through a direct effect on 
glomerular endothelial function [7] or glomerular hemodynamics. However, the evidence 
supporting this hypothesis is weak. Hypertension was not related to FGF23 and therefore 
cannot explain the rise in proteinuria with increasing FGF23 levels. Another explanation may 
be that proteinuria itself increases FGF23. This may be mediated by the association of 
proteinuria with vitamin D homeostasis [25]. Proteinuria however is associated with vitamin 
D deficiency and therefore a decline in FGF23 would have been expected, giving the 
observed increase in FGF23 levels seen upon supplementation with activated vitamin D in 
experimental models [26]. As patients with proteinuria received active vitamin D more 
frequently (shown in Table 4), this use of active vitamin D was added to the fully adjusted 
model (Table 3). Active vitamin D use however, did not explain the higher levels of FGF23 
in patients with proteinuria. Another potential mechanism that could link proteinuria with 
FGF23 levels is secondary hyperparathyroidism, induced by deficiency of vitamin D that 
accompanies proteinuria. Adding lnPTH to the fully adjusted model however, did not 
mitigate the association of proteinuria with FGF23. A more likely explanation is that the 
toxic effects of proteinuria on tubular function [27,28] also disrupt local FGF23 signaling, 
leading to a compensatory increase in FGF23 production. A final explanation might be that 
both proteinuria and an increase in FGF23 are the consequence of the same underlying 
process, such as increased oxidative stress, that could lead to both proteinuria [29] and 
FGF23 resistance [20]. An association between proteinuria and FGF23 was also noted in the 
Heart and Soul study[6]. This study included patients with a mean GFR of 76 ml/min, and 
only 4% had macroalbuminuria. Our study, with mean GFR of 37 ml/min/1.73 m2 and over 
10% of patients having proteinuria > 2 g/day, extends these observations to patients with 
more severe CKD and higher levels of proteinuria. Fliser and co-workers found an 
association between FGF23 and progression of CKD, even after correction for albumin-to-
creatinine ratio (ACR), but that correction attenuated the predictive value of FGF23[30]. In 
that study the precise relation between FGF23 and proteinuria was not studied. In the study 
by Isakova the association between FGF23 and progression to end stage kidney disease was 
no longer significant after correcting for albumin-to-creatinine ratio, eGFR, albumin and 
hemoglobin, but the risk for mortality remained significant [23]. 
We found no modulating effect of either 25D or 1,25D levels on FGF23. This lack of 
evidence for an association of FGF23 with levels of vitamin D metabolites can be explained 
by the fact that active vitamin D induces FGF23 production [26] while FGF23 in turn 
catabolizes 25D and 1,25D [31], thus counterbalancing possible relationships between 
vitamin D and FGF23. 
It needs to be pointed out that some associations present in Model 2 were no longer present in 
the analysis in which vitamin D was included. There are two factors to explain this. Firstly 
the number of participants in this latter analysis is much lower (604 in model 2; 126 in 
vitamin D analysis). In addition proteinuria was dichotomized in two categories (more or less 
than 2 gr/24 hours), which reduces the discriminatory value of this variable in linear 
regression. 
Accumulating evidence points to FGF23 as a novel risk factor for mortality and progression 
of CKD [3,23]. Our findings show that a part of the increased cardiovascular risk of smoking 
[32] and proteinuria [33] in CKD may thus be explained by its effects on FGF23, assuming 
that FGF23 has direct detrimental effects. This may indicate that FGF23 has a causal role in 
cardiovascular complications in CKD, but this still is still debated, because of the possibility 
of residual confounding within these studies and the lack of definitive proof of a 
pathobiological mechanism by which FGF23 presumably induces harm. Recent evidence 
however does suggest that FGF23 is directly involved in the evolution of pathological left 
ventricular hypertrophy in mice [9]. For some factors, like GFR[1???] and phosphate level 
[34,35], both reasonably established novel risk factors for cardiovascular disease, its 
relationship with FGF23 is well described. However, previous studies demonstrated that the 
predictive value of FGF23 for clinical endpoints remained significant, even after correcting 
for these factors that are involved in its production, providing additional arguments for the 
notion that FGF23 might be more than just a risk marker. 
Some limitations of our study need to be mentioned. First, our study is a cross-sectional 
observational analysis, thus we cannot determine temporal relationships and causality. Next, 
it could be possible that FGF23 influences proteinuria, instead of the other way around. 
Indirect evidence for the latter comes from the observation that protein (and phosphate) 
restriction improves albuminuria[36]. In addition, we also cannot answer the clinically 
relevant question whether modulating proteinuria or smoking cessation can lower FGF23 and 
if FGF23 decline accomplished by these measures reduces cardiovascular risk (independent 
from risk reduction by smoking cessation alone and proteinuria reduction). Such a question 
requires a RCT. 
There are currently two techniques available to measure FGF23: intact FGF23 and c-terminal 
FGF23. The former assay is positive only in the presence of full-length FGF23, while the 
latter also measures the c-terminal truncated FGF23. In our study we did not measure intact 
FGF23, but in advanced CKD the two assays have been shown to perform similarly [37]. We 
were able to test 25D and 1,25D levels in a subset only, which weakens our conclusion that 
vitamin D metabolites had no relation with FGF23. Indeed, a recent study suggests that 
higher FGF23 was associated with lower 1,25D levels [4]. However, proteinuria was not 
measured in that study. 
Strengths of our study are the large sample size, the prospective nature of data collection and 
the use of 24 hour urine collections instead of using albumin-to-creatinine ratio in spot urine 
samples, which provides more reliable quantitative data [38]. 
Our findings can have important implications. If FGF23 indeed has a causative role in 
cardiovascular disease and is involved in progression of CKD, an important next step would 
be to test the hypothesis that dietary or pharmacological interventions aimed at a reduction of 
FGF23 improves these outcomes. The obvious tools to lower FGF23 would be a phosphate-
restricted diet [15], phosphate-binder therapy [39-41] or calcimimetics [42]. Our findings 
support the hypothesis that early intervention aiming at reducing proteinuria and cessation of 
smoking may be another tool to reduce FGF23. 
Conclusion 
In patients with CKD FGF23 is significantly associated with proteinuria and smoking, along 
with other, already established associations, like eGFR (inverse relation), plasma phosphate 
level, PTH, history of cardiovascular disease and diabetes mellitus. The clinical relevance of 
this finding is the fact that both proteinuria and smoking are modifiable. Future prospective 
randomized trial, or post-hoc analyses of existing cohorts, can reveal if targeted anti-
proteinuric therapy lowers FGF23, and if this assumed reduction is independently associated 
with improved outcome. Since the causal relationship between FGF23 and proteinuria can be 
two-sided, an additional question is the impact of targeting FGF23 to lower proteinuria. The 
relation of FGF23 with smoking provides an additional argument to discourage this habit. 
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